These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38867679)

  • 1. How should the law respond to emerging infectious diseases: China's experience and considerations in containing COVID-19.
    Yang C; Li X
    J Glob Health; 2024 Jun; 14():03028. PubMed ID: 38867679
    [No Abstract]   [Full Text] [Related]  

  • 2. COVID-19 emergencies around the globe: China's experience in controlling COVID-19 and lessons learned.
    Jin H; Lu L; Liu J; Cui M
    Int J Qual Health Care; 2021 Feb; 33(1):. PubMed ID: 33320189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What can the world learn from China's response to covid-19?
    Tang JL; Abbasi K
    BMJ; 2021 Dec; 375():n2806. PubMed ID: 34853017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of public health tools in emerging infectious diseases.
    Tang JL; Li LM
    BMJ; 2021 Dec; 375():n2374. PubMed ID: 34853003
    [No Abstract]   [Full Text] [Related]  

  • 5. To halt the spread of imported coronavirus disease 2019 cases in China: Action and challenges.
    Fu J; Jiang C; Wang J; Li Y; Ying H
    Travel Med Infect Dis; 2021; 39():101913. PubMed ID: 33171285
    [No Abstract]   [Full Text] [Related]  

  • 6. 5. Infectious disease surveillance designated by the Infectious Disease Control Law, and the situation of emerging/re-emerging infectious diseases in Japan.
    Okabe N
    Intern Med; 2002 Jan; 41(1):61-2. PubMed ID: 11838598
    [No Abstract]   [Full Text] [Related]  

  • 7. China's COVID-19 response for the protection of rural communities.
    Zhu Y; Zhao S; Qu B
    PLoS Negl Trop Dis; 2021 Feb; 15(2):e0009018. PubMed ID: 33529211
    [No Abstract]   [Full Text] [Related]  

  • 8. Policy disparities in response to the first wave of COVID-19 between China and Germany.
    Zhang Y; Shi L; Chen H; Wang X; Sun G
    Int J Equity Health; 2021 Mar; 20(1):86. PubMed ID: 33766049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. China's practice to prevent and control COVID-19 in the context of large population movement.
    Xu TL; Ao MY; Zhou X; Zhu WF; Nie HY; Fang JH; Sun X; Zheng B; Chen XF
    Infect Dis Poverty; 2020 Aug; 9(1):115. PubMed ID: 32814591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elimination could be the optimal response strategy for covid-19 and other emerging pandemic diseases.
    Baker MG; Wilson N; Blakely T
    BMJ; 2020 Dec; 371():m4907. PubMed ID: 33561814
    [No Abstract]   [Full Text] [Related]  

  • 11. Coronavirus disease 2019 and pregnancy is déjà vu all over again.
    Rasmussen SA; Jamieson DJ
    BJOG; 2022 Jan; 129(2):188-191. PubMed ID: 34379870
    [No Abstract]   [Full Text] [Related]  

  • 12. Emerging infectious diseases and the law.
    Richards EP
    Emerg Infect Dis; 2001; 7(3 Suppl):543. PubMed ID: 11485660
    [No Abstract]   [Full Text] [Related]  

  • 13. Practical laboratory considerations amidst the COVID-19 outbreak: early experience from Singapore.
    Tan SS; Yan B; Saw S; Lee CK; Chong AT; Jureen R; Sethi S
    J Clin Pathol; 2021 Apr; 74(4):257-260. PubMed ID: 32198190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pains and Gains from China's Experiences with Emerging Epidemics: From SARS to H7N9.
    Wei P; Cai Z; Hua J; Yu W; Chen J; Kang K; Qiu C; Ye L; Hu J; Ji K
    Biomed Res Int; 2016; 2016():5717108. PubMed ID: 27525272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experts' Perceptions on China's Capacity to Manage Emerging and Re-emerging Zoonotic Diseases in an Era of Climate Change.
    Hansen A; Xiang J; Liu Q; Tong MX; Sun Y; Liu X; Chen K; Cameron S; Hanson-Easey S; Han GS; Weinstein P; Williams C; Bi P
    Zoonoses Public Health; 2017 Nov; 64(7):527-536. PubMed ID: 28009103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Countries of origin of imported COVID-19 cases into China and measures to prevent onward transmission.
    Zhang ZB; Li L; Qin PZ; Li K; Huang Y; Luo L; Ou CQ
    J Travel Med; 2020 Dec; 27(8):. PubMed ID: 32841347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guangdong's experience in defeating the COVID-19.
    Chen H; Shi L; Zhang Y; Wang X; Sun G
    Medicine (Baltimore); 2021 May; 100(18):e25881. PubMed ID: 33951003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention and Control Measures for Imported SARS-CoV-2 Transmission During the Postpandemic Period in Shenzhen, China.
    He X; Gong F; Sun X; Hu G; Lin J
    Disaster Med Public Health Prep; 2022 Mar; 17():e143. PubMed ID: 35241200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Experience of Greece as a Model to Contain COVID-19 Infection Spread.
    Delinasios GJ; Fragkou PC; Gkirmpa AM; Tsangaris G; Hoffman RM; Anagnostopoulos AK
    In Vivo; 2021; 35(2):1285-1294. PubMed ID: 33622932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Travel-screening documentation to enable the "Identify-Isolate-Inform" framework for emerging infectious diseases: It's all in the details.
    Sánchez SM; Searle EF; Rubins D; Dutta S; Ware W; Biddinger PD; Shenoy ES
    Infect Control Hosp Epidemiol; 2020 Dec; 41(12):1449-1451. PubMed ID: 32847641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.